Publications by authors named "Irina Kadyrova"

4 Publications

  • Page 1 of 1

Proinflammatory cytokines and colorectal cancer - the impact of the stage.

Contemp Oncol (Pozn) 2020 4;24(4):207-210. Epub 2021 Jan 4.

Karaganda Medical University, Karaganda, Kazakhstan.

Colorectal cancer is one of the most often diagnosed malignant tumors. In Kazakhstan, high incidence of CC is registered along with other oncology diseases. Despite a significant progress in the disease treatment achieved lately, CC is still one of the major reasons of mortality due to oncologic pathologies. To study the samples MilliplexMap HumanCirculationBiomarker panel in blood serum was used. XMap-based Fluorescence immunoassay was implemented, which comprised magnetic-bead-based simultaneous fluorescence detection of IL-6, IL-8, MIF, FGF-2, SCF, TGF, TNF, TRAIL analytes. Proinflammatory biomarker concentration detection at different CC stages allows to reveal the dynamics of inflammatory response of the organism to tumor and to use them (biomarkers) in further diagnostic and forecast in particular in CC. As a result of our study, it was found that IL-6, which showed the brightest reaction, due to its range of change and considerable shift already in the I stage can be recommended as a component of a complex diagnostic panel. Such markers as FGF2 and MIF also have a role in CC early stage detection.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5114/wo.2020.102551DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836277PMC
January 2021

Psoriasis Is Associated With Elevated Gut IL-1α and Intestinal Microbiome Alterations.

Front Immunol 2020 1;11:571319. Epub 2020 Oct 1.

Laboratory of Human Microbiome and Longevity, National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.

Background: Psoriasis is a chronic inflammatory condition that predominantly affects the skin and is associated with extracutaneous disorders, such as inflammatory bowel disease and arthritis. Changes in gut immunology and microbiota are important drivers of proinflammatory disorders and could play a role in the pathogenesis of psoriasis. Therefore, we explored whether psoriasis in a Central Asian cohort is associated with alterations in select immunological markers and/or microbiota of the gut.

Methods: We undertook a case-control study of stool samples collected from outpatients, aged 30-45 years, of a dermatology clinic in Kazakhstan presenting with plaque, guttate, or palmoplantar psoriasis ( = 20), and age-sex matched subjects without psoriasis ( = 20). Stool supernatant was subjected to multiplex ELISA to assess the concentration of 47 cytokines and immunoglobulins and to 16S rRNA gene sequencing to characterize microbial diversity in both psoriasis participants and controls.

Results: The psoriasis group tended to have higher concentrations of most analytes in stool (29/47 = 61.7%) and gut IL-1α was significantly elevated (4.19-fold, = 0.007) compared to controls. Levels of gut IL-1α in the psoriasis participants remained significantly unaltered up to 3 months after the first sampling ( = 0.430). Psoriasis was associated with alterations in gut , including elevated and decreased and abundance, but no association was observed between gut microbial diversity or ratios and disease status.

Conclusions: Psoriasis may be associated with gut inflammation and dysbiosis. Studies are warranted to explore the use of gut microbiome-focused therapies in the management of psoriasis in this under-studied population.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2020.571319DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559734PMC
May 2021

Correction to: The life expectancy of patients with metabolic syndrome after weight loss: study protocol for a randomized clinical trial (LIFEXPE-RT).

Trials 2019 12 12;20(1):716. Epub 2019 Dec 12.

Department of Laparoscopic & Bariatric Surgery of Astana Medical University, Beybitshilik, Street 49A, Nur-Sultan, Kazakhstan, 010000.

Following publication of the original article [1], the authors notified us of a typing error in spelling Dr. Yeleuov's name. The original publication has been corrected.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13063-019-3861-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907125PMC
December 2019

The life expectancy of patients with metabolic syndrome after weight loss: study protocol for a randomized clinical trial (LIFEXPE-RT).

Trials 2019 Apr 8;20(1):202. Epub 2019 Apr 8.

Department of Laparoscopic & Bariatric Surgery of Astana Medical University, Beybitshilik street 49A, 010000, Nur-Sultan, Kazakhstan.

Background: To date, surgeons and physicians have found positive results treating metabolic syndrome with surgical and non-surgical weight loss therapies. The purpose of this study was to evaluate changes in telomere length in patients with metabolic syndrome after weight loss.

Methods/design: This study is a three-arm randomized controlled trial. The first group is composed of patients who have undergone stapleless bypass surgery (one anastomosis gastric bypass with an obstructive stapleless pouch and anastomosis (LOAGB-OSPAN)). The second group of patients underwent standard gastric bypass surgery (laparoscopic mini-gastric bypass-one anastomosis gastric bypass (LMGB-OAGB). The patients in the third group received non-surgical weight loss therapy, including a hypocaloric diet with energy restriction (- 500 kcal/day). The aim is to compare changes-telomere length, body mass index, comorbidities, and quality of life-in patients with metabolic syndrome after weight loss.

Discussion: To the best of our knowledge, this is the first randomized study to simultaneously compare the effects of surgical and non-surgical weight loss on changes in telomere length. It could provide a solution to the growing problem of metabolic syndrome. Normalization of the body mass index results in improvements in the health of patients with metabolic syndrome.

Trial Registration: ClinicalTrials.gov, NCT03667469 . Registered on 11 September 2018.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13063-019-3304-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454761PMC
April 2019